Antaros Medical is contributing to new data presented by Professor Rohit Loomba at this year’s AASLD the Liver Meeting. The presented data look at treatment effects of an FGF21 analogue on spleen volume in metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH) patients. Spleen volume was reduced with treatment.
Already in early stages of metabolic dysfunction-associated steatotic liver disease (MASLD; previously called non-alcoholic fatty liver disease or NAFLD), a sub-clinical portal venous pressure increase can be observed Increased pressure in the portal vein will force blood back into the splenic vain, causing the spleen to increase in volume. Spleen volume measured with magnetic resonance imaging (MRI) can therefore provide a non-invasive tool to reflect this pathophysiological process and provides a way of assessing treatment effects in clinical trials as an indicator of reduced portal venous pressure.
Hear more about this work at AASLD the Liver Meeting 2021:
Title: Treatment with BIO89-100 led to decreased spleen volume that was correlated with relative change in liver fat volume and Pro-C3 level in a Phase 1b/2a, placebo-controlled, double-blind, NASH Proof of Concept (POC) study
Abstract number: 139
Session: Parallel 21: NAFLD and NASH: Clinical Trials of Novel Therapeutics
Time: Sunday, November 14th, 6:30 PM – 8:00 PM EST